Narrative review suggests adjuvant pembrolizumab benefits selected high-risk renal cell carcinoma patients
Old cancer drugs failed, but one new drug saves high-risk kidney patients today
This narrative review evaluates adjuvant therapies for renal cell carcinoma, including cytokine-based immunotherapy, VEGF-targeted agents, a…
Doctors finally have a powerful new tool to stop kidney cancer from coming back after surgery, but it only works for specific patients.
Phase 2 trial of pembrolizumab and DNA vaccines in metastatic prostate cancer shows no significant difference
Prostate Cancer Vaccine Strategy Shows Tumor Responses, But One Arm Adds Risk
This early Phase 2 trial evaluated pembrolizumab combined with pTVG-HP or pTVG-AR DNA vaccines in 60 patients with metastatic castration-res…
A two-vaccine strategy did not improve survival over a single vaccine in advanced prostate cancer, yet both approaches shrank tumors in some…
Pembrolizumab adjuvant therapy trial for hepatocellular carcinoma recurrence-free survival
Pembrolizumab May Cut Liver Cancer Return After Surgery
This is a Phase 3 randomized controlled trial in 959 participants with hepatocellular carcinoma who had a complete radiological response aft…
After liver surgery, pembrolizumab may help keep hepatocellular carcinoma from returning, offering new hope for patients with complete tumor…
Preclinical report suggests combined ARSB and pembrolizumab inhibits melanoma progression in mice
Mouse model shows combined ARSB and pembrolizumab slows melanoma growth
This preclinical report evaluates the combination of recombinant human Arylsulfatase B (ARB) and pembrolizumab in a B16F10 syngeneic mouse m…
In a lab mouse model, combining a specific enzyme with pembrolizumab slowed tumor growth and improved survival, offering early clues for fut…
Pembrolizumab Plus Paclitaxel Improves Survival in Recurrent Ovarian Carcinoma Compared to Paclitaxel Alone
New Drug Combo Extends Survival for Tough Ovarian Cancer
This randomised, double-blind phase 3 study evaluated pembrolizumab plus paclitaxel versus placebo plus paclitaxel in 643 female participant…
This new combination offers a meaningful survival boost for women with recurrent ovarian cancer that has become resistant to standard treatm…
Narrative review examines abscopal effect potential in non-small cell lung cancer multimodality therapies
When One Tumor Shrinks, Others Can Too—Here’s How
This narrative review evaluates the abscopal effect in non-small cell lung cancer patients treated with radiotherapy, lung ablation, or immu…
A new review explains how treating one lung tumor can help shrink tumors elsewhere in the body, offering a new way to think about cancer tre…
Immune checkpoint inhibitors targeting PD-1/PD-L1 and CTLA-4 show improved risk discrimination for immune-toxicity-associated systemic injury
New Tool Predicts Immune Drug Organ Damage
This translational multicohort study evaluated patients receiving immune checkpoint inhibitors in United States electronic health record dat…
A new system helps doctors predict which patients might suffer dangerous organ injury from powerful cancer drugs, giving them time to act so…
Review: PD1/PDL1 spatial interactions predict pembrolizumab response in metastatic urothelial carcinoma
New Scan Shows Exactly Which Immune Cells Fight Cancer
This review discusses a proof-of-concept study examining PD1/PDL1 spatial interactions in tumor samples from patients with metastatic urothe…
This new method lets doctors see exactly which immune cells are actually fighting the tumor, not just hanging out nearby.
Five medications including daptomycin and durvalumab show positive association with drug-induced eosinophilic pneumonia in database analysis
15,000 Cases Found: Which Drugs Harm Your Lungs?
A retrospective pharmacovigilance investigation analyzed 15,374 cases in FAERS and Vigibase databases to identify drug-induced eosinophilic …
A massive data review reveals which medicines might silently damage your lungs.
Comprehensive review compares ICI-based regimens and ICI-TKI combinations against sunitinib in metastatic renal cell carcinoma
Kidney Cancer Treatment Just Took a Sharp Turn
This comprehensive review evaluates contemporary immune checkpoint inhibitor (ICI)-based regimens and ICI-tyrosine kinase inhibitor (TKI) co…
New kidney cancer treatments help patients live longer with fewer side effects than older drugs, giving more people a fighting chance agains…
Real-world analysis finds 34% grade 3-4 adverse events in mRCC patients on immune-based combos
Kidney Cancer Treatment: Real-World Side Effects Are Less Severe Than Expected
A retrospective cohort analysis of 2,401 patients with metastatic renal cell carcinoma receiving first-line immune-based combination therapy…
Real-world kidney cancer patients experience fewer severe side effects from immunotherapy than clinical trials suggest, offering relief to t…
Narrative review discusses immune checkpoint inhibitors in lung cancer patients
New Hope for Lung Cancer Patients
This narrative review examines immune checkpoint inhibitors (ICIs), including PD-1/PD-L1 and CTLA-4 inhibitors, for patients with lung cance…
Lung cancer patients now have a fighting chance as new medicines help the body's own immune system attack tumors instead of just killing cel…